Bio Tech
In short · bullish · Updated 10h ago
Genentech secured a licensing agreement with Earendil for bispecific antibody therapies in a deal valued at over $1.5 billion. Meanwhile, Telix Pharmaceuticals is purchasing ITM for $1.65 billion upfront to broaden its radiopharmaceutical footprint, and Bio-Techne shareholders approved a take-private deal with Merck KGaA. Additionally, Muju Earth launched an automated soil device designed to lower UK farming tilling costs.
This brief
4 stories on Bio Tech
The Market Overview is open to everyone. The Bio Tech brief - and every other one - needs an account, which is free and keeps your place, your streak and the terms you save.
Free · no card